Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Recruiting

Phase 2

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Code:

NCT06760156

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tafasitamab

Lenalidomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2025-05-06.